Dr. Richard Eglen Joins PerkinElmer to Lead Discovery and Research Reagents Business
Eglen joins PerkinElmer from DiscoveRx, where he held the positions of chief scientific officer and executive vice president for research and development. Prior to that, Eglen worked for more than 20 years in several executive positions within the pharmaceutical, diagnostic and biotech industries.
Eglen has a Ph.D. in Molecular Pharmacology from Trent University in Nottingham, United Kingdom. He has been published in more than 250 scientific papers and books and holds several patents, many of which focus on key drug discovery targets such as GPCRs, kinases and ion channels. He also holds several patents relating to novel technologies for enabling drug discovery and other types of research. Eglen serves on numerous journal editorial boards and is a board member of the Society for BioMolecular Sciences (SBS).
Most read news
Topics
Organizations
Other news from the department people
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.